Busulfan: all 322 studies that test it
Page 3 of 4. Open to participants first (42), then studies with results posted, then the rest; newest registration first within each.
- Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATGCompletedNCT02916979Phase 1
- BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's LymphomaStatus unknownNCT02836639Phase 2
- Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell TransplantationStatus unknownNCT02784561Phase 4
- International Randomised Phase III Clinical Trial in Children With Acute Myeloid LeukaemiaActive, not recruitingNCT02724163Phase 3
- Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed LymphomaWithdrawnNCT02701673Phase 1/2
- BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCTCompletedNCT02670252Phase 3
- Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer PatientsStatus unknownNCT02670109Phase 2
- URMC Related Haplo-identical Donor BMTCompletedNCT02660281Phase 1
- High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous DiseaseActive, not recruitingNCT02629120Phase 1/2
- Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings SarcomaCompletedNCT02472392Phase 1
- Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid MalignanciesStatus unknownNCT02333838Phase 2
- Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)TerminatedNCT02310997Phase 2
- Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT02250937Phase 2
- Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02129582Phase 1
- Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in MyelomaWithdrawnNCT02114502Phase 2
- Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell TransplantCompletedNCT02083250Phase 1
- CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell TransplantActive, not recruitingNCT02061800Phase 1/2
- Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL.Status unknownNCT02047578Phase 2
- Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in GRDStatus unknownNCT02034630Phase 1/2
- Study of Sequential High-dose Chemotherapy in Children With High Risk MedulloblastomaTerminatedNCT02025881Phase 1/2
- Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin LymphomaActive, not recruitingNCT01961063Phase 1
- Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell TransplantCompletedNCT01959477Early Phase 1
- Busulfan and Melphalan Conditioning in Multiple MyelomaStatus unknownNCT01923935Phase 2
- Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years OldCompletedNCT01916252Phase 3
- Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing SarcomaWithdrawnNCT01795430Not applicable
- Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin LymphomasStatus unknownNCT01786018Phase 2
- Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01758328Phase 1
- Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide MaintenanceCompletedNCT01702831Phase 2
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune DeficienciesActive, not recruitingNCT01652092Not applicable
- Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning RegimensCompletedNCT01572181Phase 2
- Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed InfantsSuspendedNCT01512888Phase 1/2
- Auto Transplant for High Risk or Relapsed Solid or CNS TumorsCompletedNCT01505569Not applicable
- Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-MatchTerminatedNCT01500161Phase 2
- Pharmacokinetic Study of Busulfan in Allogeneic Stem Cell Transplantation in Adult Patients With Acute LeukemiaStatus unknownNCT01498016Phase 2
- Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic MalignanciesCompletedNCT01471067Phase 1
- PRO#0118: Decitabine Plus Mini Flu-BuCompletedNCT01455506Phase 1
- Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid MalignanciesCompletedNCT01421173Phase 1
- Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)Status unknownNCT01339988Phase 4
- Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Chronic Granulomatous Disease(CGD)Status unknownNCT01338675Phase 1/2
- Hematopoietic Stem Cell Transplantation With Targeted Busulfan and Fludarabine in Pediatric AMLStatus unknownNCT01274195Phase 2
- Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AMLCompletedNCT01191957Phase 3
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 DeficiencyActive, not recruitingNCT01176006Phase 2
- Hematopoietic Stem Cell Transplant for Fanconi AnemiaCompletedNCT01071239Phase 2
- BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)Status unknownNCT01063439Phase 2
- Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid MalignanciesCompletedNCT01056614Phase 2
- CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor TransplantCompletedNCT01049854Phase 2
- Targeted, Dose-Escalation Busulfan-Etoposide as Prep RegimenCompletedNCT01048827Phase 1
- Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in RemissionCompletedNCT01020734Phase 2
- Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk LeukemiaCompletedNCT01020539Phase 1
- Hematopoietic Stem Cell Transplantation Based on Pharmacokinetic and Pharmacodynamic ModelingCompletedNCT01018446Phase 1
- Autologous Transplantation for Chronic Myelogenous LeukemiaCompletedNCT01003054Phase 2
- Study in Localized and Disseminated Ewing SarcomaCompletedNCT00987636Phase 3
- Busulfan in Multiple MyelomaTerminatedNCT00934232Phase 1
- Pilot Study of Unrelated Cord Blood TransplantationTerminatedNCT00916045Phase 2
- Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and ThymoglobulinTerminatedNCT00915811Phase 2
- Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AMLStatus unknownNCT00887042Phase 1/2
- Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS)CompletedNCT00885833Phase 1/2
- Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)TerminatedNCT00881556Early Phase 1
- Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan RegimenCompletedNCT00852163Phase 2
- Study of Busulfan for Refractory Central Nervous System (CNS) TumorsWithdrawnNCT00836628Phase 1
- Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)Status unknownNCT00815568Phase 2
- Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological CancerCompletedNCT00806767Phase 2
- Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to TreatmentCompletedNCT00802568Phase 2
- Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT00750126Phase 2
- Allogeneic Transplantation for Pediatric Leukemias With Unrelated DonorsStatus unknownNCT00679536Phase 1/2
- Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMMLTerminatedNCT00669890Phase 1
- Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete RemissionCompletedNCT00667927Phase 1
- Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid TumorCompletedNCT00638898Phase 1
- Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological CancerCompletedNCT00627666Phase 2
- MT2004-30: Tomotherapy for Solid TumorsTerminatedNCT00623077Phase 1
- Reduced Intensity AlloSCT in(CML) With Persistent DiseaseTerminatedNCT00531310Phase 2
- Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCTCompletedNCT00516152Phase 2
- Cord Blood Expansion on Mesenchymal Stem CellsCompletedNCT00498316Phase 1
- Autologous Stem Cell Transplants for Chronic Myelogenous LeukemiaWithdrawnNCT00446173Phase 2
- Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid TumorsStatus unknownNCT00436761Phase 1
- Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid MalignanciesCompletedNCT00410982Phase 1
- Stem Cell Transplant in Sickle Cell Disease and ThalassemiaActive, not recruitingNCT00408447Phase 2
- Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT00402558Phase 1
- Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid CancerCompletedNCT00346359Phase 2
- Respiratory Side Effects of Busulfan High Dose Chemotherapy in a Pediatric PopulationStatus unknownNCT00328029Phase 2
- Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple MyelomaCompletedNCT00313625Phase 2
- Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First RemissionCompletedNCT00305708Phase 1/2
- Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00304018Phase 1
- Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00301951Phase 1
- Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic CancerWithdrawnNCT00301912Phase 2
- Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic CancerCompletedNCT00296023Not applicable
- IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell ImmunodeficiencyCompletedNCT00228852Phase 1/2
- Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic MalignanciesCompletedNCT00208923Phase 2
- Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT00186966Phase 3
- Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell DiseaseCompletedNCT00186810Phase 2
- Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation: a Pharmacokinetic StudyStatus unknownNCT00156858Not applicable
- Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and LymphomasCompletedNCT00152126Not applicable
- Use of Busulfan as Conditioning Agent for a Second Stem Cell TransplantCompletedNCT00092937Phase 1
- Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant DiseasesStatus unknownNCT00084695Phase 2
- Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative DisorderCompletedNCT00054340Phase 1/2
- Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic CancerCompletedNCT00053196Phase 2
- Study of Gelonin Purging of Autologous Stem Cells for TransplantationTerminatedNCT00043810Phase 1/2
- Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or ThalassemiaTerminatedNCT00034528Phase 2
- Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00027924Phase 2